GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascendis Pharma A/S (BSP:A1SN34) » Definitions » Cyclically Adjusted Price-to-FCF

Ascendis Pharma A/S (BSP:A1SN34) Cyclically Adjusted Price-to-FCF : (As of Jun. 10, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Ascendis Pharma A/S Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Ascendis Pharma A/S Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Ascendis Pharma A/S's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascendis Pharma A/S Cyclically Adjusted Price-to-FCF Chart

Ascendis Pharma A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Ascendis Pharma A/S Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Ascendis Pharma A/S's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Ascendis Pharma A/S's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ascendis Pharma A/S's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascendis Pharma A/S's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Ascendis Pharma A/S's Cyclically Adjusted Price-to-FCF falls into.



Ascendis Pharma A/S Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Ascendis Pharma A/S's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Ascendis Pharma A/S's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-9.685/118.4000*118.4000
=-9.685

Current CPI (Mar. 2024) = 118.4000.

Ascendis Pharma A/S Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -1.411 99.700 -1.676
201409 -0.613 99.700 -0.728
201412 -1.479 99.400 -1.762
201503 -1.007 100.200 -1.190
201506 -2.102 100.300 -2.481
201509 -2.233 100.200 -2.639
201512 -1.740 99.800 -2.064
201603 -2.462 100.200 -2.909
201606 -1.995 100.600 -2.348
201609 -2.320 100.200 -2.741
201612 -1.928 100.300 -2.276
201703 -2.231 101.200 -2.610
201706 -2.748 101.200 -3.215
201709 -2.965 101.800 -3.448
201712 -2.573 101.300 -3.007
201803 -3.849 101.700 -4.481
201806 -2.163 102.300 -2.503
201809 -5.441 102.400 -6.291
201812 -3.846 102.100 -4.460
201903 -6.337 102.900 -7.292
201906 -0.573 102.900 -0.659
201909 -5.834 102.900 -6.713
201912 -4.802 102.900 -5.525
202003 -8.205 103.300 -9.404
202006 -7.454 103.200 -8.552
202009 -7.615 103.500 -8.711
202012 -11.173 103.400 -12.794
202103 -10.753 104.300 -12.207
202106 -13.364 105.000 -15.070
202109 -12.369 105.800 -13.842
202112 -14.404 106.600 -15.998
202203 -13.006 109.900 -14.012
202206 -12.250 113.600 -12.768
202209 -9.484 116.400 -9.647
202212 -14.449 115.900 -14.761
202303 -14.727 117.300 -14.865
202306 -14.365 116.400 -14.612
202309 -11.773 117.400 -11.873
202312 -4.006 116.700 -4.064
202403 -9.685 118.400 -9.685

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Ascendis Pharma A/S  (BSP:A1SN34) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Ascendis Pharma A/S Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Ascendis Pharma A/S's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Ascendis Pharma A/S (BSP:A1SN34) Business Description

Industry
Traded in Other Exchanges
Address
Tuborg Boulevard 12, Hellerup, DNK, DK-2900
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates in North America, China, and Europe and derives the majority of its revenue from North America.

Ascendis Pharma A/S (BSP:A1SN34) Headlines

No Headlines